NHSE Interim treatment options

Message from Steve Williamson, NHS England Lead Cancer Pharmacist

29th April 2020 – NHSE Interim treatment options

 

Dear Colleague

You may have seen that NICE has published an updated table to the SACT clinical guideline NG161 listing many new Interim treatment options earlier this week. See https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381. There are a couple of points of clarification for providers to note:

  • Enzalutamide for prostate cancer states it is subject to confirmation, we can confirm enzalutamide is approved, and there is no need to check for confirmation. A Blueteq form for abiraterone for patients unable to tolerate enzalutamide will be made available in due course.
  • Gilteritinib is approved for relapsed /refractory AML and not newly diagnosed AML.
  • Nivolumab is approved in MSI-H colorectal cancer, the wording states ‘subject to confirmation’ we can confirm this is approved and there is no need to check for confirmation.
  • A blueteq form for polatuzumab will be released in due course as NHSE is currently working with the company to ensure there is stock available for the selected patient group.

We advise all these indications are to be billed through the usual specialised commissioning route, as there is additional COVID19 funding available for them.  Any drugs where we have changed the CDF pathway are not funded through CDF as there is separate COVID19 funding for them. We are pleased to note that the manufacturers of many of these drugs have worked with NHS England and offered additional discounts to support the NHS during COVID19.

Latest News

By UK SACT Protocols Pilot Team on 20th November 2026

Have Your Say: Review the First UK SACT Protocol and Provide Feedback

Dear Colleagues working in cancer services We are writing to invite you to review and provide feedback on the first protocol produced as part of the UK SACT Protocols Pilot.…

Read article
By Mohammed Patel on 11th November 2026

UK BMT Pharmacists Group Educational Meeting – Friday 13th November 2026. Time:14:00 to 16:00

The next UK BMT Pharmacists Group Educational Meeting is on Friday 13th November, 2pm–4pm. The sessions include: Maintenance Therapy for AML After Allogeneic BMT with Dr Mili Shah, Consultant Haematologist,…

Read article
By UK SACT Board on 9th November 2026

New UK SACT Board National Intrathecal and Intraventricular SACT Guidance

Dear colleagues, We are pleased to share the newly published UK SACT Board National Guidance on the Safe Administration of Systemic Anti-Cancer Therapies via the Intrathecal or Intraventricular Routes. This…

Read article
By BOPA Executive Committee on 9th November 2026

BOPA members flying the flag for cancer pharmacy at ESMO 2026

It was fantastic to see BOPA members representing cancer pharmacy at ESMO Congress 2026 in Madrid, which brought together the global cancer community from 23 to 27 October to share…

Read article